Trials / Completed
CompletedNCT00798759
Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN
Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and XALATAN®
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 236 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®) | Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost. |
| DRUG | Latanoprost ophthalmic solution 0.005% (XALATAN®) | Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost. |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2008-11-26
- Last updated
- 2012-06-01
- Results posted
- 2012-04-23
Source: ClinicalTrials.gov record NCT00798759. Inclusion in this directory is not an endorsement.